异溴米特 | 466-14-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 异溴米特
• 英文名称: 2-ethyl-2-bromo-3-methyl-butyric acid amide
• 英文别名: 2-Aethyl-2-brom-3-methyl-buttersaeure-amid；2-bromo-2-ethyl-3-methyl-butanamide；ibrotamide；2-bromo-2-ethyl-3-methylbutanamide
• CAS: 466-14-8
• 化学式: C₇H₁₄BrNO
• 分子量: 208.098
• InChiKey: YQZUCYWIGWXZQO-UHFFFAOYSA-N

物化性质

• 熔点：
  50.5°C
• 沸点：
  270.1±23.0 °C(Predicted)
• 密度：
  1.3583 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924199090

反应信息

• 作为产物：
  描述：

  2-ethyl-2-bromo-3-methyl-butyryl bromide 在 氨 、 苯 作用下， 生成 异溴米特
  参考文献：
  名称：

  DE533313

  摘要：

  公开号：

文献信息

• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129284A2

  公开（公告）日：1984-12-27

  Improved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C3-C4 diols or a 1-substituted azacycloalkyl-2-one. This composition provides marked transepidermal and percutaneous delivery of the selected pharmaceutically-active agent. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了含有一种药物活性剂和渗透增强剂 1-十二烷基氮杂环庚烷-2-酮的改良外用药物组合物。这种药剂与某些 C3-C4 二醇或 1-取代偶氮环烷基-2-酮结合使用时，可达到选定的水平。这种组合物能明显地经皮和经皮给药。此外，还公开了一种全身或局部治疗对所选活性剂有反应的某些病理和病症的方法。
• Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129285A2

  公开（公告）日：1984-12-27

  Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration-enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and percutaneous delivery of the active selected. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了一种外用药物组合物，该组合物包含一种药物活性剂和一种新型的渗透增强载体或载体。载体或载体包括 N-（2-羟乙基）吡咯烷酮和 "细胞包膜紊乱化合物 "的二元组合。这些组合物能明显地经皮和经皮递送所选的活性物质。此外，还公开了一种全身或局部治疗对所选活性物质有反应的某些病理和病症的方法。